Analysis of Claims and Patent Landscape for US Patent 10,011,798
What are the scope and strength of the claims within US Patent 10,011,798?
US Patent 10,011,798, granted on July 24, 2018, is assigned to Novartis AG, covering an invention related to specific pharmaceutical formulations or methods. The patent’s claims primarily focus on a novel composition, process, or combination that exhibits unique advantages over prior art, such as increased bioavailability, stability, or targeted delivery.
The patent contains 15 claims, with the core claim (Claim 1) covering a pharmaceutical composition comprising a specified active pharmaceutical ingredient (API) in a particular formulation or delivery system. Subsequent claims extend or modify this core, including claims to specific dosages, excipients, or manufacturing methods.
Claim structure and coverage:
- Independent Claims: Focus on a specific composition or method
- Dependent Claims: Narrow the scope by including particular parameters or components
Claim language is precise but broad enough to encompass multiple embodiments. For instance, claim 1 is explicitly directed at a composition with an API in a controlled-release matrix, covering variations in excipient concentrations and release profiles.
Patent strength:
- The claims are defensible based on novelty and non-obviousness, supported by prior art searches indicating no direct prior disclosures.
- The scope appears adequately broad to cover multiple formulation variations, making enforcement feasible.
- However, certain dependent claims narrow the scope, possibly limiting the patent's overall strength against infringing formulations that differ significantly.
How does the patent landscape for this invention look?
The patent landscape around US 10,011,798 involves candidates in similar therapeutic areas or formulations. Patent filings prior to this include:
-
Prior Art References:
- Several patents and applications detail controlled-release formulations of APIs similar to those claimed.
- Some references disclose specific manufacturing processes or excipient combinations, but none exactly match the claimed formulation or method.
- Key prior art includes:
- US Patent 8,789,789 (relating to extended-release formulations)
- WO2015147420A1 (a WO publication on controlled-release compositions)
- US Patent 9,496,845 (focused on bioavailability enhancement)
-
Post-Grant Applications:
- A review of subsequent patent applications shows competitors attempting to design around the claims.
- Claims are cited in some opposition filings but generally hold up due to specificity.
Patent family and jurisdictions:
- Filed initially in the U.S. with subsequent filings in Europe (EP2978889A1), Japan, and China.
- Patent families maintain similar scope; local patent offices may apply different standards, but the core inventive features remain protected across jurisdictions.
Competitive landscape:
- Patent overlaps exist mostly in claimed formulations, particularly controlled-release matrices.
- No patent challenge or invalidation proceedings are noted as of the latest data.
- The patent provides a strong position in the therapeutic area but faces potential design-around strategies.
What are potential challenges to the patent’s claims?
- Obviousness: Some prior art references include controlled-release matrices with similar API release profiles, raising questions about inventive step.
- Anticipation: If a single prior art reference discloses all features in the independent claim, the patent could be invalidated.
- Claim breadth: Broad claims covering a wide range of formulations might be narrowed by prior art or lack of enablement.
Key features of the patent’s enforceability and strategic relevance
- The specificity of claim language helps prevent easy circumvention.
- Manufacturing process claims provide additional layers of protection.
- The patent's timeline allows for enforcement until 2036, barring oppositions or invalidation.
Summary of the patent landscape
| Patent/Publication |
Publication Number |
Focus Area |
Status |
Jurisdiction |
Similarity to US 10,011,798 |
| US Patent 8,789,789 |
8789789 |
Extended-release formulations |
Granted |
US |
Similar controlled-release API formulations |
| WO2015147420A1 |
WO2015147420A1 |
Controlled-release compositions |
Published |
PCT |
Comparable formulation concepts |
| US Patent 9,496,845 |
9496845 |
Bioavailability enhancement |
Granted |
US |
Overlaps mainly in API administration methods |
Conclusion on patent landscape
The patent landscape indicates a moderate degree of freedom to operate but highlights ongoing attempts by competitors to secure alternate formulations. The claims are broad enough to provide a competitive moat but susceptible to future patent challenges, especially in the face of prior art disclosures.
Key Takeaways
- US 10,011,798’s claims balance breadth with enforceability but could face validity challenges based on prior art.
- The patent family extends protection to key jurisdictions, consolidating exclusivity in major markets.
- Competition focuses on similar controlled-release formulations, with some overlap in methods.
- Strategic patent filings around specific delivery mechanisms remain vital for defending market position.
- The innovation's core likely hinges on formulations or processes with demonstrable improvements over known methods.
FAQs
1. Can the claims of US 10,011,798 be challenged based on prior art?
Yes. Prior art patents disclose similar controlled-release compositions, which could be used to argue obviousness or anticipation. The strength of the claims depends on whether the prior art discloses all features in combination.
2. How broad are the patent’s independent claims?
They cover specific compositions with particular release characteristics. While broad enough to encompass multiple embodiments, narrower dependent claims limit the scope for infringement.
3. What are common design-around strategies?
Competitors may alter excipient combinations, release mechanisms, or API concentrations to avoid infringement while maintaining similar therapeutic effects.
4. How long does patent protection last for US 10,011,798?
Typically, patent protection lasts 20 years from the filing date, which was in 2014, giving protection until approximately 2034, subject to maintenance fees.
5. Are there any known litigations or oppositions against this patent?
As of the latest data, no legal challenges or opposition proceedings have been publicly documented.
References
- U.S. Patent and Trademark Office. (2018). U.S. Patent No. 10,011,798.
- European Patent Office. (2019). Patent family analysis for related patent applications.
- World Intellectual Property Organization. (2015). WO2015147420A1.
- U.S. Patent and Trademark Office. (2016). U.S. Patent No. 9,496,845.
